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ABSTRACT
Matching for HLA class I alleles, including HLA-C, is an important criterion for outcome of unrelated donor
transplantation. However, haplotype-mismatched transplantations for myeloid malignancies, mismatched for
killer immunoglobulin-like receptor (KIR) ligands in the graft-versus-host (GVH) direction, is associated with
lower rates of graft-versus-host disease (GVHD), relapse, and mortality. This study investigated the effect of
KIR ligand mismatching on the outcome of unrelated donor transplantation. The outcomes after 1571
unrelated donor transplantations for myeloid malignancies where donor–recipient pairs were HLA-A, -B, -C,
and -DRB1 matched (n  1004), GVH KIR ligand–mismatched (n  137), host-versus-graft (HVG) KIR
ligand–mismatched (n  170), and HLA-B and/or –C–mismatched but KIR ligand–matched (n  260) were
compared using Cox regression models. Treatment-related mortality (TRM), treatment failure, and overall
mortality were lowest after matched transplantations. Patients who received grafts from donors mismatched at
the KIR ligand in the GVH or HVG direction and mismatched at HLA-B and/or C but matched at the KIR
ligand had similar rates of TRM, treatment failure, and overall mortality. There were no differences in
leukemia recurrence between the 4 groups. These results do not support the choice of an unrelated donor on
the basis of KIR ligand mismatch determined from HLA typing.
© 2006 American Society for Blood and Marrow Transplantation
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KIR Ligand Incompatibility in Unrelated Donor Transplantation 877NTRODUCTION
Donor and recipient matching of major histocom-
atibility complex (MHC) class I alleles is an impor-
ant determinant of clinical outcomes of unrelated
onor hematopoietic cell transplantation (HCT), in-
uencing the risk of graft rejection, graft-versus-host
isease (GVHD), and relapse. HLA-A and -B antigen
ismatches are independent risk factors for graft fail-
re [1,2], and mismatches for HLA-A, -B, and -C are
isk factors for GVHD [3]. In 1 study, HLA-C mis-
atch was an independent determinant of graft rejec-
ion after adjusting for other class I antigen mis-
atches [4]. Although speciﬁc effects of mismatch at
ifferent MHC class I 1oci on survival remain uncer-
ain, the number of disparate loci appears to be in-
ersely correlated with survival [5,6].
Some epitopes of MHC class I molecules, partic-
larly HLA-C, function as ligands for killer immuno-
lobulin-like receptors (KIRs), which are important to
he recognition of target cells by natural killer (NK)
ells [7]. A single KIR recognizes determinants shared
etween members of a “group” of MHC class I alleles.
or example, KIR2DL1 recognizes group 2 (Asn77
ys80) HLA-C molecules, KIR2DL2/3 recognizes
roup 1 (Ser77 Asn80) HLA-C molecules, KIR3DL1
ecognizes the HLA-Bw4 epitope, and KIR3DL2 rec-
gnizes HLA-A3 and A11 molecules [7,8]. Recog-
ition of the relevant MHC class I molecule by a given
nhibitory KIR results in inhibition of the NK cell,
hereas nonrecognition leaves activation signals un-
pposed, promoting target cell lysis [8]. In 1 report of
aplotype-mismatched, T-cell–depleted transplanta-
ion, mismatching for KIR class I epitopes in the
raft-versus-host (GVH) direction was associated with
reduction in relapse, graft rejection, and GVHD in
atients with high-risk acute myeloid leukemia (AML)
9,10]. In a mouse model, alloreactive NK cells dem-
nstrated a potent in vivo antileukemic effect and
liminated host T cells and antigen-presenting cells,
acilitating engraftment and preventing acute GVHD
10]. These data were not fully conﬁrmed by a subse-
uent report, however [11].
Complete matching of all HLA class I (and class II)
oci, including HLA-C, is generally advocated in unre-
ated donor HCT. However, the results observed with
aplotype-mismatched transplantations, where donor–
ecipient pairs are mismatched at the KIR ligand epitope
9,10], call this practice into question. It is possible that
y mismatching for KIR epitopes in the GVH direction,
he outcome of unrelated donorHCTmight be similarly
mproved. A recent analysis has suggested that KIR
HC class I epitope mismatching may indeed improve
he outcome of unrelated donor HCT [12]. However,
ismatching was associated with a worse outcome in a
eparate analysis of T-replete unrelated donor transplan-
ations at a single center [13]. The purpose of this anal- dsis was to investigate the effect of KIR ligandmismatch-
ng on the outcome of unrelated donor HCT using data
eported to the National Marrow Donor Program
NMDP) and the European Bone Marrow Transplant
EBMT) and Dutch registries to determine whether
here might be a beneﬁt from selecting KIR ligand-
ismatched donors.
ETHODS
nclusion Criteria
The study population included 1571 patients who
eceived unrelated donor HCT between January 1990
nd December 1999 facilitated by the NMDP in the
nited States (n  1424) or reported to the EBMT
nd Dutch registries (n  147). Recipients age  65
ears with AML, myelodysplasia (MDS) with refrac-
ory anemia (RA), RA with excess blasts (RAEB) or
xcess blasts in transformation (RAEB-T) subtypes
sing the French-American-British (FAB) criteria
14,15], or chronic myeloid leukemia (CML) were
ligible. All recipients received myeloablative regi-
ens. Recipients of previous HCT, peripheral blood
r cord blood grafts, or regimens containing Cam-
ath-1 antibodies were excluded.
LA Typing and KIR Ligand Matching of
onor–Recipient Pairs
High-resolution typing for HLA-A, -B, -C, and
DRB1 were available for all donor–recipient pairs.
ll selected donor–recipient pairs were matched for
LA-A and -DRB1 alleles. Cases were divided into
hose matched for MHC class I alleles (HLA-A, -B,
C) and those mismatched for HLA-B and/or -C
lleles. KIR ligand status of donor–recipient pairs was
etermined from HLA typing; KIR typing was not
erformed. Donor–recipient pairs mismatched for the
LA-B and/or -C loci were subdivided into KIR
igand–matched, KIR ligand–mismatched in the host-
ersus-graft (HVG) direction, and KIR ligand–mis-
atched in the GVH direction. Cases with bidirec-
ional mismatches of KIR ligands were included with
hose mismatched in the GVH direction. KIR ligand
ismatch was deﬁned by the absence of donor KIR
igand class I alleles in the recipient using an algorithm
escribed by Ruggeri et al [10]. The KIR and MHC
lass I ligands considered included KIR2DL1 with
roup 2 HLA-C molecules, KIR2DL2/3 with group 1
LA-C molecules, and KIR3DL1 with HLA-B mol-
cules carrying the Bw4 epitope as deﬁned by their
redicted amino acid sequences.
efinitions of Clinical Endpoints
Neutrophil recovery was deﬁned as an absolute
eutrophil count (ANC)  500/L for 3 consecutive
ays and platelet recovery  20,000/L unsupported
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S. S. Farag et al.878or 7 days. Grade 2–4 acute GVHDwas assigned to all
atients [16], and chronic GVHD was assigned to
hose patients who survived 90 days or longer [17].
reatment-related mortality (TRM) was deﬁned as
eath during continuous remission. Relapse was de-
ned as hematologic leukemia recurrence; patients
ho failed to achieve remission after transplantation
ere considered to have had recurrence at day 1.
eukemia-free survival (LFS) was deﬁned as survival
n continuous complete remission.
election of Registry Cases
All cases from the EBMT and Dutch registries
ho met the eligibility criteria as described above
ere included. However, only a subset of transplan-
ations facilitated by the NMDP in the United States
as included, based on the availability of high-resolu-
ion HLA typing and informed consent. Between
990 and 1999, the NMDP performed retrospective
igh-resolution typing for 4156 of 7594 transplanta-
ions. This subset had to have available donor and
ecipient pretransplantation samples for retrospective
yping and is representative of all transplantations
acilitated by the NMDP. The NMDP retrospectively
btained consent for study participation from surviv-
ng patients or parents/legal guardians for transplan-
ations that it facilitated in the United States during
he study period; the NMDP Institutional Review
oard waived consent for patients who died before
oliciting consent.
To address bias introduced by the inclusion of
nly a proportion of surviving patients (those consent-
ng) but all deceased patients, a sample of deceased
atients was selected using a weighted randomized
cheme that adjusts for overrepresentation of deceased
atients in the consented cohort. This weighted ran-
omized scheme was developed based on all survivors
n the NMDP database. A logistic regression model
as ﬁt to identify the factors that predicted whether a
atient had consented or not consented to use of data
ollected by the NMDP. This analysis found that the
ollowing factors were associated with the likelihood
f a patient consenting: age at transplantation, disease
ype, race, sex, cytomegalovirus serologic status, and
ountry of transplantation (United States vs non–
nited States). Using estimated consenting probabil-
ties from this model based on the characteristics of
ead patients, the biased coin method of randomiza-
ion was performed to determine which of the dead
atients likely would have consented to participate had
hey been alive. Thus this procedure includes the
reconsented dead patients at the same probability as
urviving patients who consented to participate. Ap-
roximately 13% of the surviving patients failed to
onsent, and 12% of the dead patients were deleted by
he weighted randomized method. The above-de- Hcribed methods were tested several times, and on
very occasion the proportion of deleted dead patients
as similar.
tatistical Analysis
Baseline variables were compared between the
roups using the 2 statistic for categorical variables
nd the Kruskal-Wallis test for continuous variables.
robabilities of overall survival (OS) and LFS were
alculated using the Kaplan-Meier estimator [18]. For
S, death from any cause was considered an event,
nd patients surviving at last follow-up were censored.
or LFS, relapse or death (treatment failure) was
onsidered an event, and patients surviving in contin-
ous complete remission were censored at last follow-
p. Probabilities of neutrophil and platelet recovery,
cute and chronic GVHD, TRM, and relapse were
alculated using the cumulative incidence function
19]. For neutrophil and platelet recovery and
VHD, death without an event was the competing
vent; for TRM, relapse was the competing event;
nd, for relapse, treatment-related death was the com-
eting event.
Adjusted probabilities of OS and LFS were esti-
ated using the Cox proportional hazards regression
odel with consideration of the variables in the ﬁnal
ultivariate models [20]. Multivariate models were
onstructed using stepwise forward selection, with a
value  .01 considered signiﬁcant. (A signiﬁcance
evel of .01 rather than .05 was chosen because of the
ultiple comparisons performed in this study.) All
ariables met the proportional hazards assumption.
he variable for donor–recipient HLA compatibility
as retained in all steps of model building. Other
ariables considered were recipient age, disease type
nd disease status at HCT, sex of the recipient and
onor, conditioning regimen (irradiation vs nonirra-
iation-containing), GVHD prophylaxis regimen (ex
ivo T-cell depletion vs T-replete), year of transplan-
ation (1990-1995 vs 1996-1999), and the use or non-
se of antithymocyte globulin (ATG). There were
o ﬁrst-order interactions between the variable for
onor–recipient HLA compatibility and other vari-
bles studied. Because the data were obtained from 3
ndependent registries, all multivariate analyses were
tratiﬁed by the variable for registry source. No sta-
istically signiﬁcant center effects were noted. All re-
orted P values are 2-sided. Analyses were performed
sing PROC PHREG in SAS version 8.2 (SAS Insti-
ute, Cary, NC).
ESULTS
atients
Patient, disease, and transplant characteristics for
LA-matched and mismatched transplantations ac-
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KIR Ligand Incompatibility in Unrelated Donor Transplantation 879ording to KIR ligand status are shown in Table 1.
ome 64% of transplants were matched at HLA-A,
B, -C, or -DRB1; 9% were mismatched in the GVH
IR ligand direction, 11% were mismatched in the
VG direction, and 16% were mismatched at HLA-B
nd/or -C but matched at the KIR ligand. Thirteen of
37 cases in the GVH KIR ligand group were mis-
atched in both the GVH and HVG directions.
roups were similar in terms of patient, disease, and
ransplant characteristics. Data on the use of ATG
ere available for 1424 of 1571 patients. Of these,
4% received ATG. The median follow-up for survi-
ors after HLA-matched, GVH KIR ligand–mis-
atched, HVG KIR ligand–mismatched, and HLA-B
nd/or –C–mismatched transplantations was 60, 68,
able 1. Patient, Disease and Transplant Characteristics of Donor–Rec
GVH KIR Ligand
Mismatch*
HVG KI
Mism
137 1
atient sex
Male, n (%) 72 (53) 102 (6
atient age (years), n (%)
<10 9 (7) 3 (2
10–19 10 (7) 20 (1
20–29 17 (13) 37 (2
30–39 40 (29) 41 (2
40–49 44 (32) 53 (3
50–65 17 (12) 16 (9
/R sex, n (%)
M/M 44 (32) 60 (3
M/F 35 (26) 39 (2
F/M 28 (20) 42 (2
F/F 30 (22) 29 (1
ear of BMT, n (%)
1990–1995 57 (42) 67 (3
1996–1999 80 (58) 103 (6
LA mismatches, n (%)
HLA-B 2 (2) 3 (2
HLA-C 80 (58) 104 (6
HLA-B and -C 55 (40) 63 (3
isease, n (%)
AML 46 (33) 50 (2
CML 75 (55) 92 (5
MDS 16 (12) 28 (1
isease status, n (%)‡
Early 69 (50) 90 (5
Advanced 68 (50) 80 (4
Unknown 0
egimen, n (%)
TBI  other 116 (85) 138 (8
Bu/Cy  other 21 (16) 32 (1
VHD prophylaxis, n (%)
T-cell depletion 27 (20) 44 (2
No T-cell depletion 110 (80) 126 (7
ollow-up, months
Median (range) 68 (12–143) 69 (1
, recipient; D, donor; M, male; F, female; BMT, bone marrow tr
HLA mismatch refers to mismatching at the HLA-B and/or -C lo
GVH KIR ligand mismatched group included 13 cases with bidir
AML and MDS patients in ﬁrst complete remission, and CML pat
to have early disease; all others are classiﬁed as advanced diseas9 and 59 months, respectively. 5eutrophil and Platelet Recovery
Of the 1571 recipients, 1284 (82%) could be
valuated for neutrophil recovery and 1179 (75%)
ould be evaluated for platelet recovery. There were
o signiﬁcant differences in the probability of neutro-
hil or platelet recovery after HLA-matched and
LA-mismatched transplantations. The probability
f neutrophil recovery at day 30 was 95% after
LA-matched transplantations, 91% after GVH
IR ligand–mismatched transplantations, 93% after
VG KIR ligand–mismatched trasnsplantations, and
3% after and HLA-mismatched but KIR ligand–
atched transplantations. Corresponding probabili-
ies of platelet recovery at day 100 were 69%, 55%,
airs by HLA and KIR Ligand Matching
nd HLA-Mismatch, KIR
Ligand Match†
Full HLA
Match P Value
260 1004
142 (55) 564 (56) .58
.10
16 (6) 44 (4)
26 (10) 81 (8)
54 (21) 160 (16)
74 (28) 287 (29)
65 (25) 299 (30)
25 (10) 133 (13)
.30
85 (32) 398 (40)
64 (24) 238 (24)
57 (22) 165 (16)
54 (21) 201 (20)
.51
97 (37) 424 (42)
163 (63) 580 (58)
62 (24) 0
134 (51) 0
64 (25) 0
.15
77 (30) 246 (25)
149 (57) 584 (58)
34 (13) 174 (17)
.56
126 (48) 536 (53)
133 (51) 467 (47)
1 (<1) 1 (<1)
.81
215 (83) 817 (78)
45 (17) 187 (19)
.15
54 (21) 185 (18)
206 (79) 819 (82)
59 (5–130) 60 (6–154)
tation; Bu, busulfan; Cy, cyclophosphamide.
l KIR ligand mismatches.
chronic phase (CP) at the time of transplantation were consideredipient P
R Liga
atch
70
0)
)
2)
2)
4)
1)
)
5)
3)
5)
7)
9)
1)
)
1)
7)
9)
4)
7)
3)
7)
0
1)
9)
6)
4)
9–130)
ansplan
ci.
ectiona
ients in5%, and 62%.
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S. S. Farag et al.880cute and Chronic GVHD
Grade 2–4 acute GVHD developed in 503 of 1001
ecipients of HLA-matched transplantations, 74 of
37 GVH KIR ligand–mismatched transplantations,
6 of 169 HVG KIR ligand–mismatched transplanta-
ions, and 140 of 260 HLA-B and/or –C–mismatched
ut KIR-matched transplantations. Rates of acute
rade 2–4 GVHD were similar in all groups (Table 2).
n contrast, the rate of grade 3–4 acute GVHD was
igniﬁcantly higher after any mismatched transplanta-
ion than after HLA-matched transplantation (Table 2).
mong recipients of mismatched transplantations,
ates of grade 2–4 or grade 3–4 acute GVHD did not
iffer by KIR ligand status.
Among those patients surviving for 90 days or
onger, chronic GVHD developed in 476 of 956 re-
ipients of HLA-matched transplants, in 40 of 131
ecipients of GVH KIR ligand–mismatched trans-
lants, in 62 of 159 recipients of HVG KIR ligand–
ismatched transplants, and in 99 of 245 recipients of
LA-B and/or –C–mismatched but KIR-matched
ransplants. Risks of chronic GVHD were similar in
ll groups and independent of KIR ligand status
Table 2).
reatment-Related Mortality
Death from treatment-related causes occurred in
able 2. Results of Multivariate Analysis Comparing Rates of Acute an
VG KIR-Mismatched, and HLA-Mismatched Transplantations
Grade 2–4 acute GVHD*
GvH KIR-mismatched vs. HLA- and KIR-matched
KIR-matched, HLA-mismatched vs. HLA- and KIR-matched
HvG KIR-mismatched vs. HLA- and KIR-matched
KIR-matched, HLA-mismatched vs. GvH KIR-mismatched
HvG KIR-mismatched vs. GvH KIR-mismatched
HvG KIR-mismatched vs. KIR-matched, HLA-mismatched
rade 3–4 acute GVHD†
GvH KIR-mismatched vs. HLA- and KIR-matched
KIR-matched, HLA-mismatched vs. HLA- and KIR-matched
HvG KIR-mismatched vs. HLA- and KIR-matched
KIR-matched, HLA-mismatched vs. GvH KIR-mismatched
HvG KIR-mismatched vs. GvH KIR-mismatched
HvG KIR-mismatched vs. KIR-matched, HLA-mismatched
hronic GVHD‡
GvH KIR-mismatched vs. HLA- and KIR-matched
KIR-matched, HLA-mismatched vs. HLA- and KIR-matched
HvG KIR-mismatched vs. HLA- and KIR-matched
KIR-matched, HLA-mismatched vs. GvH KIR-mismatched
HvG KIR-mismatched vs. GvH KIR-mismatched
HvG KIR-mismatched vs. KIR-matched, HLA-mismatched
In all groups the risk of grade 2–4 acute GVHD was higher after t
conﬁdence interval [CI], 1.3–2.31; P  .001) and irradiation-co
In all groups, the risk of grade 3–4 acute GVHD was lower if tra
P  .001).
In all groups, the risk was lower if male recipients of grafts from
(RR, 0.65; 99% CI, 0.49–8.86; P  .001) and recipients of non33 of 967 recipients of HLA-matched transplants, in m1 of 133 recipients of GVH KIR ligand–mismatched
ransplants, in 103 of 161 recipients of HVG KIR ligan-
–mismatched transplants, and in 133 of 251 HLA-B
nd/or –C–mismatched but KIR-matched transplants.
RM was lowest after HLA-matched transplantation
Table 3; Figure 1) and was signiﬁcantly higher after any
ismatched transplantations, but did not differ by KIR
igand status.
elapse
Leukemia recurred after transplantation in 156 of
67 recipients of HLA-matched transplants, in 24 of
33 recipients of GVHKIR ligand–mismatched trans-
lants, in 16 of 161 recipients of HVG KIR ligand–
ismatched transplants, and in 42 of 251 HLA-B
nd/or –C–mismatched but KIR-matched transplants.
eukemia recurrence was similar in all groups and
ndependent of KIR ligand matching status (Table 3;
igure 2).
eukemia-Free Survival
Treatment failure (relapse or death from any
ause) occurred in 589 of 967 recipients of HLA-
atched transplants, in 105 of 133 recipients of GVH
IR ligand–mismatched transplants, in 119 of 161
ecipients of HVG KIR ligand–mismatched trans-
lants, and in 175 of 251 HLA-B and/or -C–mis-
nic GVHD After Matched, GVH KIR-Mismatched,
Hazard Ratio
(99% Confidence Interval) P Value
1.08 (0.78–1.51) .53
1.17 (0.90–1.50) .12
1.28 (0.95–1.73) .04
1.07 (0.73–1.57) .63
1.18 (0.78–1.79) .30
1.10 (0.77–1.57) .50
1.64 (1.11–2.42) .001
1.41 (1.01–1.96) .01
1.91 (1.33–2.73) <.001
0.86 (0.55–1.35) .39
1.16 (0.72–1.87) .42
1.35 (0.88–2.08) .07
0.72 (0.47–1.11) .05
0.89 (0.66–1.20) .33
1.01 (0.70–1.44) .97
1.24 (0.76–2.01) .26
1.39 (0.82–2.36) .11
1.13 (0.73–1.73) .48
ntation of non–T-cell–depleted grafts relative risk [RR], 1.76; 99%
g conditioning regimen (RR, 1.42; 99% CI; 1.09–1.83; P  .001).
ations were performed after 1995 (RR, 0.73; 99% CI, 0.57– 0.93;
nors and female recipients of grafts from a male or female donor
l–depleted grafts (RR, 1.44; 99% CI, 1.08–1.92; P  .001).d Chro
ranspla
ntainin
nsplant
male doatched but KIR-matched transplants. Treatment
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KIR Ligand Incompatibility in Unrelated Donor Transplantation 881ailure was lowest after HLA-matched transplantation
Table 3; Figure 3). Treatment failure was signiﬁ-
antly higher after mismatched transplantations and
id not differ by KIR ligand status.
verall Survival
Death from any cause occurred in 582 of 1004
ecipients of HLA-matched transplants, in 106 of 137
ecipients of GVH KIR ligand–mismatched trans-
lants, in 120 of 170 HVG KIR ligand–mismatched
ransplants, and in 177 of 260 HLA-B and/or -C–mis-
atched but KIR-matched transplants. Mortality was
owest after HLA-matched transplantation (Table 3;
igure 4). Mortality was signiﬁcantly higher after mis-
atched transplantations and did not differ by KIR
able 3. Results of Multivariate Analysis Comparing Rates of TRM, R
IR-Matched, GVH KIR-Mismatched, HvG KIR-Mismatched, and HL
reatment-related mortality*
GvH KIR-mismatched vs. HLA and KIR-matched
KIR-matched, HLA-mismatched vs. HLA- and KIR-matched
HvG KIR-mismatched vs. HLA- and KIR-matched
KIR-matched, HLA-mismatched vs. GvH KIR-mismatched
HvG KIR-mismatched vs. GvH KIR-mismatched
HvG KIR-mismatched vs. KIR-matched, HLA-mismatched
elapse†
GvH KIR-mismatched vs. HLA- and KIR-matched
KIR-matched, HLA-mismatched vs. HLA- and KIR-matched
HvG KIR-mismatched vs. HLA- and KIR-matched
KIR-matched, HLA-mismatched vs. GvH KIR-mismatched
HvG KIR-mismatched vs. GvH KIR-mismatched
HvG KIR-mismatched vs. KIR-matched, HLA-mismatched
reatment failure‡
GvH KIR-mismatched vs. HLA- and KIR-matched
KIR-matched, HLA-mismatched vs. HLA- and KIR-matched
HvG KIR-mismatched vs. HLA- and KIR-matched
KIR-matched, HLA-mismatched vs. GvH KIR-mismatched
HvG KIR-mismatched vs. GvH KIR-mismatched
HvG KIR-mismatched vs. KIR-matched, HLA-mismatched
verall mortality§
GvH KIR-mismatched vs. HLA- and KIR-matched
KIR-matched, HLA-mismatched vs. HLA- and KIR-matched
HvG KIR-mismatched vs. HLA- and KIR-matched
KIR-matched, HLA-mismatched vs. GvH KIR-mismatched
HvG KIR-mismatched vs. GvH KIR-mismatched
HvG KIR-mismatched vs. KIR-matched, HLA-mismatched
In all groups, TRM was higher in older recipients (age 20–49 years
CI, 1.91–4.39; P .001) and those with advanced disease (not in
P  .001). TRM was signiﬁcantly lower in CML recipients co
0.61–0.95; P  .002).
In all groups, patients with advanced disease (not in ﬁrst CR, ﬁrst
CI, 1.75–4.26; P  .001) and those with CML and MDS, less li
P  .001 and RR, 0.48; 99% CI, 0.29–0.80; P  .001, respecti
In all groups, treatment failure was higher in older recipients (age 2
2.55; 99% CI, 1.81–3.60; P  .001) and those with advanced di
CI, 1.31–1.93; P  .001). Treatment failure was signiﬁcantly lo
In all groups, mortality was higher in older recipients age 20–49 y
99% CI, 1.80–3.65; P  .001) and those with advanced disease
1.31–1.95; P  .001), but was signiﬁcantly lower in CML recipigand status. gISCUSSION
The superior results associated with KIR ligand
ncompatibility in the GVH direction in haplotype-
ismatched HCT [9,10], and subsequently in 1 small
tudy of unrelated donor HCT [12], suggest a possible
linical beneﬁt from KIR ligand incompatibility in a
ider transplantation setting. It is thought that KIR
igand incompatibility in the GVH direction results in
arly recovery of donor alloreactive NK cells with
otent antileukemic activity. In an animal model of
-cell–depleted grafts, such cells are associated with
radication of leukemia and of host antigen-present-
ng cells, preventing GVHD even in the setting of
igniﬁcant histoincompatibility [10]. The Perugia
Treatment Failure, and Overall Mortality After HLA- and
atched, KIR-Matched Transplantations
Hazard Ratio
(99% Confidence Interval) P Value
1.95 (1.43–2.68) <.001
1.51 (1.16–1.96) <.001
1.75 (1.32–2.32) <.001
0.77 (0.54–1.11) .07
0.89 (0.61–1.31) .45
1.16 (0.82–1.63) .27
1.56 (0.88–2.75) .04
1.11 (0.70–1.75) .56
0.75 (0.38–1.47) .27
0.71 (0.37–1.38) .19
0.48 (0.21–1.10) .02
0.68 (0.32–1.45) .18
1.90 (1.44–2.51) <.001
1.44 (1.15–1.80) <.001
1.49 (1.15–1.93) <.001
0.76 (0.55–1.04) .02
0.78 (0.55–1.11) .07
1.04 (0.76–1.41) .76
1.94 (1.47–2.57) <.001
1.45 (1.17–1.83) <.001
1.51 (1.16–1.98) <.001
0.75 (0.54–1.04) .02
0.78 (0.55–1.11) .07
1.04 (0.76–1.43) .75
.34; 99% CI, 1.66–3.32; P .001; age 50–65 years; RR, 2.90; 99%
, ﬁrst CP, or RA) at transplantation (RR, 1.34; 99% CI, 1.07–1.67;
d to recipients with AML or myelodysplasia (RR, 0.76; 99% CI,
RA) at transplantation were more likely to relapse (RR, 2.73; 99%
relapse compared to AML patients (RR, 0.45; 99% CI, 0.30–0.68;
ears: RR, 2.06; 99% CI 1.56–2.73; P  .001; age 50–65 years: RR,
ot in ﬁrst CR, ﬁrst CP, or RA) at transplantation (RR, 1.59; 99%
CML recipients (RR 0.70; 99% CI, 0.58–0.85; P  .001).
R, 2.09; 99% CI, 1.57–2.78; P  .001; age 50–65 years; RR, 2.56;
n ﬁrst CR, ﬁrst CP or RA) at transplantation (RR, 1.60; 99% CI,
R, 0.69; 99% CI, 0.57–0.85; P  .001).elapse,
A-Mism
; RR, 2
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mpare
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kely to
vely).
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S. S. Farag et al.882f haploidentical transplantation [9,10]. In the context
f an aggressively T-cell–depleted haploidentical
raft with a high stem cell dose and no posttransplan-
ation immune suppression, a marked reduction in
elapse and GVHD and excellent engraftment was
emonstrated in very–high-risk adults with AML
9,10]. The results of our study contrast with these
bservations, because we did not observe any beneﬁ-
ial effect of KIR ligand incompatibility in the GVH
irection on any of the major clinical endpoints of
nrelated donor HCT. Patients receiving HLA-
atched transplants had signiﬁcantly lower TRM, re-
apse, treatment failure, and overall mortality than
atients receiving transplants from GVH KIR ligand–
ncompatible donors. Furthermore, we could not
emonstrate any signiﬁcant beneﬁt of KIR ligand in-
ompatibility in either the GVH or HVG direction on
ajor clinical endpoints compared with HLA-mis-
igure 1. Cumulative incidence of TRM by donor–recipient HLA
nd KIR ligand matching. The 5-year rates were 45% after HLA-
atched and KIR ligand–matched transplantations (n  967), 62%
fter GVH KIR ligand–mismatched transplantations (n  133),
4% after HLA-B and/or –C–mismatched but KIR-matched trans-
lantations (n 251), and 65% after HVG KIR ligand–mismatched
ransplantations (n  161) (P  .001).
igure 2. Cumulative incidence rates of relapse by donor–recipient
LA and KIR ligand matching. The 5-year rates were 16% after
LA-matched and KIR ligand–matched transplantations (n 967),
8% after GVH KIR ligand–mismatched transplantations (n 
33), 17% after HLA-B and/or –C–mismatched but KIR-matched
ransplantations (n  251), and 10% after HVG KIR ligand–
ismatched transplantations (n  161) (P  not signiﬁcant). tatched transplantations without KIR ligand mis-
atch. Studies investigating the signiﬁcance of KIR
igand incompatibility in mismatched transplantation
ave yielded mixed and conﬂicting results. Although
ur results using the largest study population to date
re consistent with previous reports showing no sig-
iﬁcant beneﬁt of GVH KIR ligand mismatching in
nrelated donor HCT [13,21,22], other studies have
eported a variable reduction in relapse [12,23] and
mprovement in OS [12], although none has reported
rotection from GVHD. In an additional study, KIR
igand incompatibility was associated with inferior
urvival [24].
Differences in sample size, transplantation tech-
iques, and methods of determining KIR ligand in-
ompatibility may explain the differences among the
urrent study and previous reports. Thus far, most
eports are limited to single institutions, whereas the
igure 3. Probability of LFS by donor–recipient HLA and KIR
igand matching. The 5-year rates were 39% after HLA-matched
nd KIR ligand–matched transplantations (n  967), 20% after
VH KIR ligand–mismatched transplantations (n  133), 29%
fter HLA-B and/or –C–mismatched but KIR-matched transplan-
ations (n  251), and 26% after HVG KIR ligand–mismatched
ransplantations (n  161) (P  .001).
igure 4. Probability of OS by donor–recipient HLA and KIR
igand matching. The 5-year rates were 42% after HLA-matched
nd KIR ligand–matched transplantations (n  967), 24% after
VH KIR ligand–mismatched transplantations (n  133), 31%
fter HLA-B and/or –C–mismatched but KIR-matched transplan-
ations (n  251), and 30% after HVG KIR ligand–mismatched
ransplantations (n  161) (P  .001).
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KIR Ligand Incompatibility in Unrelated Donor Transplantation 883urrent analysis includes more than 1500 patients. In
ddition, the beneﬁcial effect of GVH KIR ligand
ismatching was originally described in haplotype-
ismatched transplantations performed using a high
D34 cell dose after extensive T-cell depletion of
he graft to prevent GVHD without additional post-
ransplantation immunosuppression [9,10]. In con-
rast, almost 80% of patients in our study received
nmanipulated grafts. Furthermore, although the
oses of T cells infused are not available, it is likely
hat T-cell depletion was only partial, because most
ethods used (eg, use of T-lymphocyte–speciﬁc
ntibodies and complement, elutriation) are likely
o have achieved only a 2–3 log depletion, compared
ith the more extensive (4–5 log) depletion of
cells performed in the haplotype-mismatched
ransplantations. In the current analysis, the use of
-depleted grafts (ex vivo) or ATG (resulting in some
n vivo T-cell depletion) failed to demonstrate an
ffect of KIR ligand mismatching on transplantation
utcome. This is consistent with recent data showing
hat T-cell alloreactivity dominates over NK cell al-
oreactivity in minimally T-cell–depleted HLA-non-
dentical transplantations [19,21]. Furthermore, the
resence of signiﬁcant numbers of T cells in the graft
ay affect NK cell receptor acquisition after trans-
lantation [25]. A comparison of NK cell receptor
xpression of baseline recipient and donor-derived
ngrafting NK cells at 100 days after volunteer unre-
ated donor (VUD) transplantation showed dimin-
shed reconstitution of KIR expression with increased
xpression of the activating receptor NKG2D in T-
eplete transplantations compared with T-cell–de-
leted transplantations [25]. This was also associated
ith a higher proportion of engrafted NK cells secret-
ng interferon- in response to interleukin (IL)-12 and
L-18 [25]. These observations are consistent with our
bservation of better outcomes with better-matched
rafts, because any effect of KIR ligand incompatibil-
ty may have been masked by the effect of alloreactive
cells and/or of posttransplantation immunosuppres-
ion.
It is important to note that we did not use KIR
enotyping to classify our cases, but instead relied
ntirely on HLA typing to determine KIR ligand
ncompatibility and hence NK cell alloreactivity
9,13]. Central to this algorithm is the principle that
K cell alloreactivity occurs when the HLA genotype
f the donor includes a KIR epitope that is not part of
LA genotype of the recipient cells, with the assump-
ion that the donor’s NK cells express inhibitory KIR
or the donor’s own HLA ligands [8]. Recent evidence
ndicates that this assumption may not always be cor-
ect, however. KIR and HLA genotypes segregate
ndependently, with the expressed KIR repertoire reg-
lated by KIR genotype and not by HLA genotype
26-29]. In a signiﬁcant proportion of cases, therefore,ndividuals may lack KIR for their HLA ligands, and
ice versa [30]. Indeed, in a recent study of T-cell–
epleted haplotype-mismatched transplantations, KIR-
riven alloreactivity was better predicted if donor KIR
enotype was considered along with the HLA type of
he recipient [31]. Relapses were signiﬁcantly less fre-
uent, and survival improved in cases where the re-
ipient was lacking the HLA ligand for the donor-
nhibitory KIR as assessed by KIR typing [31]. More
ecently, this “missing ligand” algorithm was also
hown to be strongly predictive of outcome even in
-cell–depleted HLA-matched sibling donor trans-
lantations for AML and MDS, where in this setting
60% of HLA-matched recipients were missing 1 or
ore ligands for their own and their donor’s inhibi-
ory KIR [32]. Finally, a further limitation imposed by
he lack of KIR genotyping is the potential confound-
ng effect of activating KIR, which could not be ex-
mined in our study but may be important in deter-
ining outcome [33-36].
In summary, the results of the current study of
nrelated donor HCT show that HLA mismatch is
ssociated with higher TRM, treatment failure, and
verall mortality regardless of the presence or absence
f KIR ligand mismatch. Furthermore, no advantage
f GVH KIR ligand incompatibility for any of the
linical endpoints examined was observed compared
ith other HLA-mismatched VUD transplantations.
ccordingly, our results do not support the choice of
nrelated donor HCT on the basis of KIR ligand
ismatching using HLA typing alone, even when a
LA-B or -C mismatch is necessary.
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